nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR1D—meninx—peripheral nervous system neoplasm	0.0411	0.127	CbGeAlD
Atomoxetine—HTR1B—dura mater—peripheral nervous system neoplasm	0.0391	0.12	CbGeAlD
Atomoxetine—HTR1D—dura mater—peripheral nervous system neoplasm	0.0379	0.116	CbGeAlD
Atomoxetine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0221	0.068	CbGeAlD
Atomoxetine—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.0168	0.0517	CbGeAlD
Atomoxetine—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0163	0.0501	CbGeAlD
Atomoxetine—NPY1R—nerve—peripheral nervous system neoplasm	0.0145	0.0445	CbGeAlD
Atomoxetine—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.012	0.0368	CbGeAlD
Atomoxetine—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.0116	0.0357	CbGeAlD
Atomoxetine—HTR6—ganglion—peripheral nervous system neoplasm	0.0101	0.0309	CbGeAlD
Atomoxetine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00809	0.0249	CbGeAlD
Atomoxetine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.00756	0.0233	CbGeAlD
Atomoxetine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00609	0.0187	CbGeAlD
Atomoxetine—HTR1B—ganglion—peripheral nervous system neoplasm	0.00606	0.0186	CbGeAlD
Atomoxetine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.00601	0.0185	CbGeAlD
Atomoxetine—HTR1D—ganglion—peripheral nervous system neoplasm	0.00587	0.0181	CbGeAlD
Atomoxetine—HTR2C—ganglion—peripheral nervous system neoplasm	0.00581	0.0179	CbGeAlD
Atomoxetine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00576	0.0177	CbGeAlD
Atomoxetine—HTR2A—pons—peripheral nervous system neoplasm	0.00569	0.0175	CbGeAlD
Atomoxetine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00551	0.017	CbGeAlD
Atomoxetine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00491	0.0151	CbGeAlD
Atomoxetine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00485	0.0149	CbGeAlD
Atomoxetine—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00298	0.00916	CbGeAlD
Atomoxetine—HTR2A—nerve—peripheral nervous system neoplasm	0.00295	0.00908	CbGeAlD
Atomoxetine—HTR2A—ganglion—peripheral nervous system neoplasm	0.00292	0.00897	CbGeAlD
Atomoxetine—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00288	0.00887	CbGeAlD
Atomoxetine—HTR1B—brainstem—peripheral nervous system neoplasm	0.00264	0.00811	CbGeAlD
Atomoxetine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.00261	0.00804	CbGeAlD
Atomoxetine—HTR1D—brainstem—peripheral nervous system neoplasm	0.00255	0.00785	CbGeAlD
Atomoxetine—HTR2C—brainstem—peripheral nervous system neoplasm	0.00253	0.00777	CbGeAlD
Atomoxetine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.0024	0.00737	CbGeAlD
Atomoxetine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.00211	0.00649	CbGeAlD
Atomoxetine—Ephedrine—BCHE—peripheral nervous system neoplasm	0.00194	0.282	CrCbGaD
Atomoxetine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.00129	0.00396	CbGeAlD
Atomoxetine—HTR2A—brainstem—peripheral nervous system neoplasm	0.00127	0.0039	CbGeAlD
Atomoxetine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00115	0.00355	CbGeAlD
Atomoxetine—Reboxetine—ABCB1—peripheral nervous system neoplasm	0.00106	0.154	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—peripheral nervous system neoplasm	0.000973	0.141	CrCbGaD
Atomoxetine—Fluoxetine—ABCB1—peripheral nervous system neoplasm	0.000664	0.0963	CrCbGaD
Atomoxetine—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000625	0.00192	CbGeAlD
Atomoxetine—Maprotiline—ABCB1—peripheral nervous system neoplasm	0.00062	0.09	CrCbGaD
Atomoxetine—Propafenone—ABCB1—peripheral nervous system neoplasm	0.000592	0.0858	CrCbGaD
Atomoxetine—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000569	0.00175	CbGeAlD
Atomoxetine—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000535	0.00095	CcSEcCtD
Atomoxetine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000534	0.000948	CcSEcCtD
Atomoxetine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000534	0.000948	CcSEcCtD
Atomoxetine—Rash—Topotecan—peripheral nervous system neoplasm	0.000534	0.000948	CcSEcCtD
Atomoxetine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000533	0.000947	CcSEcCtD
Atomoxetine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000533	0.000947	CcSEcCtD
Atomoxetine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000532	0.000944	CcSEcCtD
Atomoxetine—Cough—Etoposide—peripheral nervous system neoplasm	0.000531	0.000943	CcSEcCtD
Atomoxetine—Headache—Topotecan—peripheral nervous system neoplasm	0.00053	0.000942	CcSEcCtD
Atomoxetine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000529	0.00094	CcSEcCtD
Atomoxetine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000529	0.00094	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000529	0.00094	CcSEcCtD
Atomoxetine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000529	0.00094	CcSEcCtD
Atomoxetine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000529	0.000939	CcSEcCtD
Atomoxetine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000529	0.000939	CcSEcCtD
Atomoxetine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000529	0.000939	CcSEcCtD
Atomoxetine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000527	0.000937	CcSEcCtD
Atomoxetine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000527	0.000936	CcSEcCtD
Atomoxetine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000527	0.000935	CcSEcCtD
Atomoxetine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000526	0.000934	CcSEcCtD
Atomoxetine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000526	0.000934	CcSEcCtD
Atomoxetine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000524	0.000931	CcSEcCtD
Atomoxetine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000524	0.000931	CcSEcCtD
Atomoxetine—Pain—Vincristine—peripheral nervous system neoplasm	0.000524	0.000931	CcSEcCtD
Atomoxetine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000524	0.000931	CcSEcCtD
Atomoxetine—Rash—Melphalan—peripheral nervous system neoplasm	0.000523	0.000928	CcSEcCtD
Atomoxetine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000522	0.000927	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00052	0.000924	CcSEcCtD
Atomoxetine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000518	0.00092	CcSEcCtD
Atomoxetine—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000517	0.000919	CcSEcCtD
Atomoxetine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000517	0.000918	CcSEcCtD
Atomoxetine—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.000516	0.000916	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000515	0.000914	CcSEcCtD
Atomoxetine—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000512	0.000909	CcSEcCtD
Atomoxetine—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000507	0.0009	CcSEcCtD
Atomoxetine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000506	0.000898	CcSEcCtD
Atomoxetine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000503	0.000893	CcSEcCtD
Atomoxetine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000503	0.000893	CcSEcCtD
Atomoxetine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000503	0.000893	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000501	0.000891	CcSEcCtD
Atomoxetine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000499	0.000886	CcSEcCtD
Atomoxetine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000499	0.000886	CcSEcCtD
Atomoxetine—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000497	0.000882	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000494	0.000877	CcSEcCtD
Atomoxetine—Infection—Etoposide—peripheral nervous system neoplasm	0.000493	0.000876	CcSEcCtD
Atomoxetine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000492	0.000875	CcSEcCtD
Atomoxetine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000492	0.000874	CcSEcCtD
Atomoxetine—Influenza—Epirubicin—peripheral nervous system neoplasm	0.00049	0.00087	CcSEcCtD
Atomoxetine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000487	0.000865	CcSEcCtD
Atomoxetine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000485	0.000861	CcSEcCtD
Atomoxetine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000485	0.000861	CcSEcCtD
Atomoxetine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000485	0.000861	CcSEcCtD
Atomoxetine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000482	0.000857	CcSEcCtD
Atomoxetine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00048	0.000853	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000479	0.00085	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000474	0.000841	CcSEcCtD
Atomoxetine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000473	0.000841	CcSEcCtD
Atomoxetine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000471	0.000837	CcSEcCtD
Atomoxetine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00047	0.000834	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000469	0.000833	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000468	0.000831	CcSEcCtD
Atomoxetine—Pain—Cisplatin—peripheral nervous system neoplasm	0.000464	0.000823	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000458	0.000813	CcSEcCtD
Atomoxetine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000457	0.000811	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000455	0.000808	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.000805	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000452	0.000803	CcSEcCtD
Atomoxetine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00045	0.0008	CcSEcCtD
Atomoxetine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000447	0.000794	CcSEcCtD
Atomoxetine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000446	0.000792	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000443	0.000787	CcSEcCtD
Atomoxetine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000442	0.000784	CcSEcCtD
Atomoxetine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00044	0.000781	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000437	0.000775	CcSEcCtD
Atomoxetine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000437	0.000775	CcSEcCtD
Atomoxetine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000436	0.000775	CcSEcCtD
Atomoxetine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000435	0.000773	CcSEcCtD
Atomoxetine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000433	0.000769	CcSEcCtD
Atomoxetine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000432	0.000767	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000429	0.000762	CcSEcCtD
Atomoxetine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000429	0.000761	CcSEcCtD
Atomoxetine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000428	0.000761	CcSEcCtD
Atomoxetine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000425	0.000754	CcSEcCtD
Atomoxetine—Pain—Etoposide—peripheral nervous system neoplasm	0.000425	0.000754	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000424	0.000754	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000424	0.000752	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000421	0.000748	CcSEcCtD
Atomoxetine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000421	0.000747	CcSEcCtD
Atomoxetine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00042	0.000745	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000419	0.000743	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.00041	0.000728	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.00041	0.000727	CcSEcCtD
Atomoxetine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000409	0.000727	CcSEcCtD
Atomoxetine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000408	0.000724	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000406	0.000721	CcSEcCtD
Atomoxetine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000405	0.00072	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—peripheral nervous system neoplasm	0.000405	0.0588	CrCbGaD
Atomoxetine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000405	0.000719	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.000717	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.000717	CcSEcCtD
Atomoxetine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000401	0.000713	CcSEcCtD
Atomoxetine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000401	0.000712	CcSEcCtD
Atomoxetine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000399	0.000708	CcSEcCtD
Atomoxetine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000395	0.000701	CcSEcCtD
Atomoxetine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000393	0.000697	CcSEcCtD
Atomoxetine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000393	0.000697	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000393	0.000697	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.00039	0.000693	CcSEcCtD
Atomoxetine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00039	0.000692	CcSEcCtD
Atomoxetine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000389	0.000691	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000387	0.000687	CcSEcCtD
Atomoxetine—Rash—Vincristine—peripheral nervous system neoplasm	0.000387	0.000687	CcSEcCtD
Atomoxetine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000386	0.000686	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000384	0.000682	CcSEcCtD
Atomoxetine—Headache—Vincristine—peripheral nervous system neoplasm	0.000384	0.000682	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.000673	CcSEcCtD
Atomoxetine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000378	0.000671	CcSEcCtD
Atomoxetine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000371	0.000659	CcSEcCtD
Atomoxetine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000364	0.000647	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000364	0.000646	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000364	0.000646	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000361	0.000641	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.000636	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000356	0.000633	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000356	0.000632	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000355	0.000631	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000353	0.000627	CcSEcCtD
Atomoxetine—Chills—Epirubicin—peripheral nervous system neoplasm	0.000352	0.000625	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000351	0.000624	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000345	0.000612	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000343	0.00061	CcSEcCtD
Atomoxetine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000342	0.000607	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000342	0.000607	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000341	0.000606	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00034	0.000604	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000598	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000598	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000336	0.000597	CcSEcCtD
Atomoxetine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000335	0.000595	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000334	0.000593	CcSEcCtD
Atomoxetine—Methadone—ABCB1—peripheral nervous system neoplasm	0.000333	0.0482	CrCbGaD
Atomoxetine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000331	0.000589	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000586	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000329	0.000584	CcSEcCtD
Atomoxetine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000328	0.000583	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000328	0.000583	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.00058	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000578	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000322	0.000572	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000571	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000564	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000316	0.000561	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000316	0.000561	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000314	0.000557	CcSEcCtD
Atomoxetine—Rash—Etoposide—peripheral nervous system neoplasm	0.000313	0.000556	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000313	0.000556	CcSEcCtD
Atomoxetine—Headache—Etoposide—peripheral nervous system neoplasm	0.000311	0.000553	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000552	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.00031	0.00055	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.000549	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—peripheral nervous system neoplasm	0.000307	0.0445	CrCbGaD
Atomoxetine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000545	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000544	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000306	0.000543	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000542	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000304	0.000539	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000301	0.000535	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000533	CcSEcCtD
Atomoxetine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000529	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000528	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000296	0.000525	CcSEcCtD
Atomoxetine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000295	0.000524	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00029	0.000516	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00029	0.000516	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00029	0.000516	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.000515	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000514	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000512	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000505	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000504	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000283	0.000503	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.000495	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000493	CcSEcCtD
Atomoxetine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000491	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000489	CcSEcCtD
Atomoxetine—Shock—Epirubicin—peripheral nervous system neoplasm	0.000274	0.000487	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000486	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000485	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000272	0.000483	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.00027	0.00048	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000269	0.000478	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000477	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000477	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000477	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000268	0.000476	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000474	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000471	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000467	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000455	CcSEcCtD
Atomoxetine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000256	0.00243	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000451	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.00045	CcSEcCtD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000253	0.00241	CbGpPWpGaD
Atomoxetine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000449	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000447	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000447	CcSEcCtD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000251	0.0024	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000251	0.00239	CbGpPWpGaD
Atomoxetine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000444	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000444	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000249	0.000442	CcSEcCtD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000248	0.00236	CbGpPWpGaD
Atomoxetine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000248	0.00044	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000246	0.00235	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000246	0.00235	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000246	0.00234	CbGpPWpGaD
Atomoxetine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000436	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000245	0.000435	CcSEcCtD
Atomoxetine—HTR2A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000244	0.00233	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000242	0.00231	CbGpPWpGaD
Atomoxetine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000242	0.00043	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000427	CcSEcCtD
Atomoxetine—HTR1D—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00024	0.00229	CbGpPWpGaD
Atomoxetine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000426	CcSEcCtD
Atomoxetine—Pain—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000423	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000423	CcSEcCtD
Atomoxetine—HTR1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000235	0.00224	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000417	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000234	0.00223	CbGpPWpGaD
Atomoxetine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000414	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000411	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000408	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000407	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000404	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000227	0.000403	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000398	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000395	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000394	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000393	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000391	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000391	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000391	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000391	CcSEcCtD
Atomoxetine—HTR6—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00022	0.00209	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000218	0.00208	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000218	0.00208	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000214	0.00204	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000377	CcSEcCtD
Atomoxetine—HTR6—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000211	0.00201	CbGpPWpGaD
Atomoxetine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000374	CcSEcCtD
Atomoxetine—HTR1D—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000209	0.00199	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000205	0.00195	CbGpPWpGaD
Atomoxetine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000364	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000204	0.00195	CbGpPWpGaD
Atomoxetine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000362	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000362	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000355	CcSEcCtD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000199	0.00189	CbGpPWpGaD
Atomoxetine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000197	0.00035	CcSEcCtD
Atomoxetine—HTR6—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000192	0.00183	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000191	0.00182	CbGpPWpGaD
Atomoxetine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000338	CcSEcCtD
Atomoxetine—HTR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000187	0.00178	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000186	0.00177	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000185	0.00176	CbGpPWpGaD
Atomoxetine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000328	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000327	CcSEcCtD
Atomoxetine—HTR6—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000183	0.00175	CbGpPWpGaD
Atomoxetine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000324	CcSEcCtD
Atomoxetine—HTR1D—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000182	0.00173	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000178	0.0017	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000178	0.0017	CbGpPWpGaD
Atomoxetine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000314	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000313	CcSEcCtD
Atomoxetine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000312	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000312	CcSEcCtD
Atomoxetine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000174	0.00031	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000303	CcSEcCtD
Atomoxetine—HTR6—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000168	0.0016	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000167	0.00159	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000167	0.00159	CbGpPWpGaD
Atomoxetine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000294	CcSEcCtD
Atomoxetine—HTR1D—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000165	0.00158	CbGpPWpGaD
Atomoxetine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000291	CcSEcCtD
Atomoxetine—HTR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000164	0.00156	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000163	0.00155	CbGpPWpGaD
Atomoxetine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000289	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000288	CcSEcCtD
Atomoxetine—HTR2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000162	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000162	0.00154	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000162	0.00154	CbGpPWpGaD
Atomoxetine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000287	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000158	0.00151	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000155	0.00148	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000155	0.00147	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000154	0.00146	CbGpPWpGaD
Atomoxetine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000272	CcSEcCtD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000153	0.00146	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000153	0.00145	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000151	0.00144	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000149	0.00142	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000148	0.00141	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000142	0.00135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000141	0.00134	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000138	0.00132	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000135	0.00129	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000135	0.00128	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000133	0.00126	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000131	0.00125	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000131	0.00125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00013	0.00124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000129	0.00123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000126	0.0012	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000124	0.00119	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000124	0.00118	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000124	0.00118	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000123	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000123	0.00117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000123	0.00117	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000121	0.00115	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000121	0.00115	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000119	0.00113	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000117	0.00112	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000117	0.00111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000113	0.00108	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000109	0.00104	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000108	0.00103	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000108	0.00103	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000107	0.00102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000107	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000106	0.00101	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000105	0.001	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000103	0.000986	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.88e-05	0.000941	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.84e-05	0.000938	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.83e-05	0.000937	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.8e-05	0.000934	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.78e-05	0.000932	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.77e-05	0.000931	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.61e-05	0.000916	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.6e-05	0.000915	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.56e-05	0.000911	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.56e-05	0.000911	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.51e-05	0.000906	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.44e-05	0.000899	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.24e-05	0.000881	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	9.18e-05	0.000875	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.17e-05	0.000874	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.08e-05	0.000865	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.01e-05	0.000859	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.85e-05	0.000844	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.83e-05	0.000841	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.64e-05	0.000823	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.57e-05	0.000817	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.39e-05	0.0008	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	8.3e-05	0.000791	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.14e-05	0.000776	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.01e-05	0.000763	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	7.98e-05	0.00076	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.96e-05	0.000759	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.88e-05	0.000751	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	7.82e-05	0.000746	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.6e-05	0.000724	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.36e-05	0.000701	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.27e-05	0.000693	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.25e-05	0.000691	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.16e-05	0.000682	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7e-05	0.000667	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.96e-05	0.000663	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.96e-05	0.000663	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.9e-05	0.000657	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.82e-05	0.00065	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.77e-05	0.000645	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	6.72e-05	0.00064	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.69e-05	0.000637	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.63e-05	0.000632	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	6.4e-05	0.00061	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.36e-05	0.000606	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.32e-05	0.000602	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.32e-05	0.000602	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.29e-05	0.0006	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	6.14e-05	0.000585	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	6.08e-05	0.00058	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6e-05	0.000572	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	6e-05	0.000571	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.96e-05	0.000568	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	5.91e-05	0.000563	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	5.89e-05	0.000561	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.83e-05	0.000556	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.83e-05	0.000556	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.83e-05	0.000556	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.81e-05	0.000553	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.79e-05	0.000552	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.78e-05	0.000551	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.67e-05	0.00054	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	5.64e-05	0.000538	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.56e-05	0.00053	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.52e-05	0.000526	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.52e-05	0.000526	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	5.43e-05	0.000518	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.4e-05	0.000515	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.38e-05	0.000513	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.32e-05	0.000507	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.1e-05	0.000486	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.06e-05	0.000482	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.02e-05	0.000479	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.96e-05	0.000472	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.42e-05	0.000421	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.42e-05	0.000421	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.36e-05	0.000416	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.3e-05	0.000409	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.23e-05	0.000403	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.1e-05	0.00039	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	3.88e-05	0.00037	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.85e-05	0.000367	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.84e-05	0.000366	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.76e-05	0.000358	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.73e-05	0.000356	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.73e-05	0.000356	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.69e-05	0.000352	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.61e-05	0.000344	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.58e-05	0.000341	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	3.57e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.56e-05	0.000339	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.55e-05	0.000338	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.55e-05	0.000338	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.52e-05	0.000335	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.51e-05	0.000334	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.45e-05	0.000328	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	3.28e-05	0.000312	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.26e-05	0.000311	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.13e-05	0.000298	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	3.08e-05	0.000294	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	3.01e-05	0.000287	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.88e-05	0.000274	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.83e-05	0.00027	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.8e-05	0.000267	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.78e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.72e-05	0.000259	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.66e-05	0.000253	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.64e-05	0.000252	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.62e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.61e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.57e-05	0.000245	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.57e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.55e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.54e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.52e-05	0.000241	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	2.52e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.49e-05	0.000238	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.47e-05	0.000236	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	2.47e-05	0.000235	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.33e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.33e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.31e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	2.31e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.31e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	2.27e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.27e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.27e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.13e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.12e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.07e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.06e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.99e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.97e-05	0.000188	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.97e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.93e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.89e-05	0.00018	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.88e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.87e-05	0.000178	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.85e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.79e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.69e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.64e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.63e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.63e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.62e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.58e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.57e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.56e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.55e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.52e-05	0.000144	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.51e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.49e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.48e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.46e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.38e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.37e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.36e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000128	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.27e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.2e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.04e-05	9.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.01e-05	9.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.97e-06	9.5e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.81e-06	8.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	6.79e-06	6.47e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	6.24e-06	5.95e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	4.08e-06	3.89e-05	CbGpPWpGaD
